98%
921
2 minutes
20
The therapeutic efficacy of radiotherapy (RT) is significantly constrained by insufficient intratumoral reactive oxygen species (ROS) generation and the inherent tumor radioresistance. To overcome these limitations, we develop a novel nanoplatform based on polymeric metal-organic frameworks (PMOFs) that uniquely integrates potent radiosensitization with X-ray-triggered, spatiotemporally synchronized release of two therapeutic gases, carbon monoxide (CO), and hydrogen sulfide (HS). This platform, termed as SHF@PMOF, is fabricated by using hafnium (Hf)-oxo clusters, porphyrin linkers (TCPP), and 1, 4-bezenedicarboxylic acid-bearing block copolymers to form highly porous structures capable of encapsulating the dual-gas donor thio-3-hydroxyflavone (SHF). Crucially, SHF@PMOF acts as a highly efficient radiosensitizer, markedly boosting the ROS generation under X-ray irradiation. Simultaneously, the same X-ray stimulus triggers the controlled corelease of CO and HS from the loaded SHF donor within the PMOF matrix. This innovative combination of intensified ROS-mediated radiotherapy and synergistic CO/HS gas therapy leads to dramatically enhanced anticancer efficacy, even at low radiation doses. Mechanistic studies reveal that the dual-gas release specifically induces mitochondrial dysfunction, characterized by impaired ATP production, disrupted Ca buffering, and inhibited NADH activity, which collectively contribute to heightened radiosensitivity and potent tumor cell killing. Both in vitro and in vivo studies conclusively demonstrate the superior performance of SHF@PMOF plus X-ray irradiation, achieving highly efficient cancer treatment through this integrated RT/gas therapy approach. This work pioneers the use of PMOF nanocarriers for codelivering a dual-gas donor and radiosensitizing components, presenting a groundbreaking strategy to amplify RT efficacy via synergistic ROS enhancement and gas-sensitized radioresponse.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1021/acsami.5c11614 | DOI Listing |
ACS Appl Bio Mater
September 2025
Division of Cardiovascular Surgery, Department of Surgery, College of Medicine, National Cheng Kung University Hospital, Tainan 704, Taiwan.
Medical gases, particularly oxygen and nitric oxide (NO), have attracted significant interest in clinical applications, notably wound healing, due to their role in enhancing cell proliferation, angiogenesis, and collagen deposition. However, the use of these gases has been limited by challenges such as inefficient gas delivery and potential toxicity to normal tissues. In this study, we elucidate a feasible approach using a porphyrin-based metal-organic framework (MOF), a unique material that shows immense potential for dual-gas-assisted wound healing.
View Article and Find Full Text PDFACS Appl Mater Interfaces
August 2025
School of Chemistry, State Key Laboratory of Fluorine & Nitrogen Chemicals, Institute of New Concept Sensors and Molecular Materials (INCSMM), Engineering Research Center of Energy Storage Materials and Devices, Ministry of Education, Xi'an Key Laboratory of Sustainable Polymer Materials, Xi'an Jiao
The therapeutic efficacy of radiotherapy (RT) is significantly constrained by insufficient intratumoral reactive oxygen species (ROS) generation and the inherent tumor radioresistance. To overcome these limitations, we develop a novel nanoplatform based on polymeric metal-organic frameworks (PMOFs) that uniquely integrates potent radiosensitization with X-ray-triggered, spatiotemporally synchronized release of two therapeutic gases, carbon monoxide (CO), and hydrogen sulfide (HS). This platform, termed as SHF@PMOF, is fabricated by using hafnium (Hf)-oxo clusters, porphyrin linkers (TCPP), and 1, 4-bezenedicarboxylic acid-bearing block copolymers to form highly porous structures capable of encapsulating the dual-gas donor thio-3-hydroxyflavone (SHF).
View Article and Find Full Text PDFJ Am Chem Soc
August 2025
Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Dongchuan Road 500, Shanghai 200241, China.
Methicillin-resistant (MRSA) represents a major clinical challenge as a predominant pathogen causing chronic and difficult-to-treat wound infections. Effective strategies that simultaneously combat bacterial infection and promote tissue regeneration are essential yet challenging for managing MRSA-related wound complications. Herein, we report the design of a novel integrated dual-gas release molecular platform, which enable the phototriggered simultaneous release of NO and CO within a single molecular entity, i.
View Article and Find Full Text PDFACS Appl Bio Mater
July 2025
Department of Chemistry, Indian Institute of Technology Kharagpur, Kharagpur, West Bengal 721302, India.
Visceral leishmaniasis (VL), caused by (), is a lethal vector-borne disease if untreated. Antimonial drugs, once effective due to their ROS-generating ability, are now largely ineffective due to rising antimony resistance in species, accentuating the urgent need for appropriate therapies. Here, we developed nanocarbon dots decorated with a flutamide-based nitric oxide donor (), which, upon visible light activation, simultaneously generates singlet oxygen (O) and nitric oxide (NO).
View Article and Find Full Text PDFAdv Mater
June 2025
NMPA Key Laboratory for Research and Evaluation of Drug Metabolism & Guangdong Provincial Key Laboratory of New Drug Screening & Guangdong-Hongkong-Macao Joint Laboratory for New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, 510515, China.
Red blood cell (RBC) transfusion therapy constitutes a vital medical intervention primarily aimed at enhancing oxygen delivery. Furthermore, RBCs possess the ability to stably bind therapeutic gas molecules such as carbon monoxide (CO) and nitric oxide (NO). As natural gas carriers, RBCs have the potential to mitigate the non-specific gas release and biosafety issues associated with conventional gas donors, which currently hinder the clinical application of gas therapy.
View Article and Find Full Text PDF